MarketVIEW Respiratory Vaccines  ·  2016 edition

Rhinovirus
Vaccines Forecast

Human rhinovirus (HRV) is the leading cause of the common cold and, across more than 160 serotypes and genotypes spanning three species, the single virus family most responsible for triggering exacerbations in COPD, asthma and cystic fibrosis, alongside a substantial share of paediatric bronchiolitis and lower respiratory illness in older adults. No HRV vaccine has yet reached clinical development; the field remains preclinical and academic, held back by the sheer diversity of circulating strains. This is a focused, Western-market commercial assessment of that opportunity, drawing on VacZine Analytics' long standing, independent authority in respiratory vaccine markets.

160+ Serotypes & Genotypes ~60% of Asthma Exacerbations Still No Vaccine in Clinical Development Western-Market Forecast to 2035
Product catalogue
VAMV066
2016 edition

Format
Executive presentation + Excel model
Coverage
Western markets
Indications
Common cold, COPD/asthma exacerbations, paediatric bronchiolitis
Forecast horizon
To 2035
Approach
LO/BASE/HI scenario value/volume demand model
Base edition
2016
Availability
Syndicated / bespoke
160+
Serotypes & genotypes across
RV-A, RV-B and RV-C
~60%
Of asthma exacerbations linked
to rhinovirus infection
0
HRV vaccine candidates in active
clinical development
2035
Forecast horizon of the
Western-market demand model
Disease background

The common cold's outsized clinical burden, and a vaccine still on the drawing board

Human rhinovirus is the most familiar of all respiratory pathogens and, at the same time, one of the least tractable vaccine targets in virology. This review sets out HRV's virology and diversity, its clinical burden across every age group, and why that diversity has kept a vaccine in the preclinical laboratory for decades.

Preclinical R&D landscape & 2025/26 update

Pathogen overview - Human rhinovirus (HRV)

Human rhinovirus (HRV) is a non-enveloped, single-stranded RNA virus of the genus Enterovirus within the Picornaviridae family, the same family that includes poliovirus and the enteroviruses behind hand, foot and mouth disease. HRV is classified into three species, RV-A, RV-B and RV-C, comprising more than 160 identified serotypes and genotypes, historically numbered serotypes 1A, 1B and 2 through 100 before genomic sequencing superseded classical serotyping and added dozens of further RV-A, RV-B and RV-C genotypes, including the RV-C species discovered only through molecular methods in 2006. Cross-protection between these types is minimal: neutralising antibody raised against one HRV type typically offers little or no protection against another, the single largest scientific obstacle to a broadly protective vaccine.

Clinically, HRV is overwhelmingly the leading cause of the common cold, but its impact reaches well beyond a mild upper respiratory illness. Respiratory viruses are detected in the large majority of asthma exacerbations in both children and adults, and HRV alone accounts for roughly 60% of virus-associated asthma exacerbations, making it the single most important viral trigger in asthma management. The same pattern recurs in chronic obstructive pulmonary disease, where HRV-triggered exacerbations are a major driver of the hospital admissions that dominate COPD's direct healthcare costs, estimated at around $9,000 per admission in the United States and Canada before indirect costs are added. In infants, HRV is consistently identified as the second most common cause of viral bronchiolitis after RSV, tends to affect somewhat older infants with an atopic family history, and, notably, early-life HRV-associated bronchiolitis is a stronger predictor of later childhood asthma than RSV-associated wheezing. In older adults and those with cystic fibrosis, HRV infection is similarly associated with acute exacerbations and a disproportionate share of hospitalisation-driven cost. The cumulative economic burden of HRV-driven common cold illness in the United States alone has long been estimated at more than $40 billion a year in direct costs and lost productivity.

Treatment today remains purely supportive; there is no licensed antiviral or vaccine. Preclinical research has continued steadily rather than stalling altogether: academic groups have shown that highly multiplexed, polyvalent inactivated vaccines covering dozens of RV-A types can raise neutralising antibody against nearly all included serotypes in non-human primates, while structural virology work has identified conserved capsid regions, including the VP4 protein, as candidate targets for a broadly cross-reactive vaccine when presented in a virus-like conformation. The J. Craig Venter Institute, among others, has pursued an NIH-funded multivalent recombinant protein approach that uses bioinformatic clustering of serotype diversity to select a manageable set of representative antigens, and a January 2026 preprint reported T-cell mediated cross-reactive immunity in a preclinical rhinovirus infection model, a complementary approach to antibody-based strategies. None of this work has yet reached human clinical trials.

2026 160+ serotypes/genotypes across RV-A, RV-B, RV-C  |  ~60% of asthma exacerbations HRV-linked  |  $40bn+ annual US economic burden  |  No candidate yet in clinical development
Product & competitor landscape

Overwhelmingly preclinical, though a first candidate has now reached Phase 1

For most of this field's history it has had no clinical-stage candidate to report; that changed in August 2026 when Apollo Therapeutics reported positive Phase 1 data for a pan-rhinovirus vaccine. The underlying barrier remains structural rather than a lack of effort: more than 160 HRV serotypes and genotypes, with little cross-protection between them, have so far defeated every attempt at a broadly protective vaccine, and the rest of the research below remains academic and industrial preclinical work rather than a competitive clinical pipeline.

  • Apollo Therapeutics (with Imperial College London / VirTus Respiratory Research)Phase 1 - positive data, Aug 2026
    APL-10456 - pan-rhinovirus adjuvanted recombinant protein vaccine
    First-in-class candidate targeting rhinovirus-driven COPD and asthma exacerbations. Topline Phase 1 data (NCT07399132, randomised, double-blind, placebo-controlled, n=144) announced 25 August 2026: a single dose was well tolerated, with no serious adverse events, and induced Th1-polarised, cross-reactive cellular immunity against all three rhinovirus species (RV-A, RV-B, RV-C). Part B (two-dose, adults 55+) data are expected Q4 2026, ahead of a planned Phase 2 COPD exacerbation-prevention trial in 1H 2027.
  • J. Craig Venter InstitutePreclinical, NIH-funded
    Multivalent recombinant protein vaccine
    Building on its own complete sequencing of all known HRV genomes, JCVI uses bioinformatic clustering to identify representative "centroid" serotypes and is developing a multivalent recombinant protein vaccine intended to cover the breadth of circulating HRV diversity with a manageable antigen count.
  • Academic consortiaPreclinical, non-human primate data
    Highly multiplexed inactivated RV-A vaccine
    A polyvalent inactivated vaccine combining up to 50 RV-A types has induced neutralising antibody against nearly all included serotypes in rhesus macaques using a prime-boost, alum-adjuvanted regimen, the field's most advanced published immunogenicity data to date, though still confined to animal models.
  • University structural virology groupsDiscovery / preclinical
    Conserved VP4 capsid epitope research
    Recent work shows that neutralising antibodies against the conserved VP4 capsid protein can be raised when VP4 peptide immunogens are presented in a virus-like conformation, a candidate route to broader cross-serotype protection than classical serotype-matched approaches.
  • Academic research groupsPreclinical, T-cell approach
    Cross-reactive T-cell immunity research
    A January 2026 preprint reported that a candidate rhinovirus vaccine evoked T-cell mediated cross-reactive immunity in a preclinical infection model, a complementary strategy to antibody-focused designs that may offer broader protection across serotypes.
  • mRNA vaccine developersEarly discovery
    mRNA platform exploration for Picornaviridae
    Groups with established mRNA respiratory vaccine platforms are exploring the wider family, though rhinovirus's non-enveloped structure poses distinct antigen-design challenges relative to enveloped targets such as RSV and influenza.
Field status
1 in Phase 1

The field's first HRV vaccine candidate has now entered clinical development. Apollo Therapeutics reported positive Phase 1 immunogenicity data for APL-10456, a pan-rhinovirus adjuvanted protein vaccine for COPD/asthma exacerbation prevention, in August 2026, with a Phase 2 trial planned for 1H 2027. Beyond this single candidate, the underlying barrier is well understood but unresolved: more than 160 serotypes and genotypes across RV-A, RV-B and RV-C, with minimal cross-protection between them, make a conventional single- or few-antigen approach ineffective. The other credible near-term paths, further multivalent recombinant protein and inactivated formulations, conserved-epitope B-cell strategies and cross-reactive T-cell approaches, remain preclinical. The VacZine Analytics model quantifies the commercial opportunity a successful broadly protective vaccine would unlock across Western markets, together with realistic timing assumptions given the field's current stage.

Scope of analysis

Six analytical layers - one commercial picture

A focused Western-market report spanning disease burden, the preclinical R&D landscape, target product profile design and LO/BASE/HI scenario demand forecasting for a vaccine opportunity that has yet to reach the clinic.

Western-market demand forecast

Value/volume demand modelling to 2035 across the major Western developed markets, for all relevant HRV indications.

Competitor & pipeline review

Full review of the preclinical research landscape, including JCVI's multivalent programme and conserved-epitope and T-cell approaches.

Target product profile design

Ideal target product profile assessment and clinical development pathway issues relevant to HRV vaccine commercialisation.

LO/BASE/HI scenario revenue forecasts

Volume and value forecasts to 2035, reflecting realistic pipeline-progression timing and alternative development-pace scenarios.

Disease burden & epidemiology

Full burden review across the common cold, COPD/asthma exacerbations and paediatric bronchiolitis, updated with current cost and prevalence data.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in HRV vaccine research, investment and future market entry planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the indication and geography framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

IndicationGeographyTarget groupVaccine statusRevenue scenario
Common cold (uncomplicated URI)Western marketsGeneral populationPreclinicalModelled
COPD/asthma exacerbation preventionWestern marketsAdults, at-riskPreclinicalModelled
Paediatric bronchiolitisWestern marketsInfantsPreclinicalModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll groupsAll scenarios$███m
Full model in the licensed workbook
Western markets · to 2035 · all HRV indications
Register interest →
Deliverables

What you receive

A focused intelligence package combining a detailed executive presentation and an LO/BASE/HI forecast model, built for organisations tracking an early-stage HRV vaccine opportunity across Western markets.

  • Executive presentation - disease background, global burden, target product profile, clinical development issues and full preclinical research landscape review
  • MS-Excel LO/BASE/HI value/volume forecast model - demand outputs to 2035 across all relevant indications
  • Western-market coverage - value and volume forecasts across the major Western developed markets
  • Preclinical intelligence - JCVI's multivalent recombinant vaccine programme, polyvalent inactivated vaccine data and conserved-epitope research
  • Updated epidemiology module - global burden data across the common cold, COPD/asthma exacerbations and paediatric bronchiolitis
  • Early decision-making support - ideal target product profile and market entrance strategy guidance for early-stage HRV vaccine planning
Target audience

Built for organisations evaluating the HRV vaccine opportunity

Most valuable to teams assessing an early-stage, high-diversity vaccine target against their own pipeline, BD ambitions or investment thesis, before the field's first clinical candidate emerges.

Vaccine developers

Positioning, target product profile and commercial feasibility assessment for HRV candidates at any preclinical stage.

Corporate strategy & BD

Validate the size and structure of a market with no incumbent vaccine, ahead of the field's eventual first clinical entrant.

Investors & analysts

Independent assessment of scientific risk and long-run commercial upside for due diligence on early-stage HRV vaccine research.

Public health & immunisation programmes

Demand modelling to support future COPD/asthma exacerbation-prevention and paediatric immunisation programme planning.

Researchers & academia

Comprehensive epidemiology and preclinical R&D landscape for grant, translational and target product profile planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions to inform long-range planning across public and private channels.

About this analysis · VAMV066

VacZine Analytics' long standing expertise in respiratory diseases means we have tracked the rhinovirus vaccine opportunity since our earliest editions, revisiting it as often as genuine scientific progress justifies rather than manufacturing false momentum. This is a focused Western-market analysis, and it has been well received by clients for the honesty and depth of its assessment of a field that remains preclinical. Few groups have followed this historically underinvested market as closely, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in 2016; any refresh would incorporate current global burden data, current preclinical R&D progress including the JCVI multivalent programme and conserved-epitope research, and realistic development-timing assumptions given the field's early stage. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV066 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc HRV vaccine analysis, a briefing call is included on request.